Tivic Health Systems, Inc. Announces Full Year 2025 Results and Business Update
San Antonio, TX – March 25, 2026 — Tivic Health Systems, Inc. (“Tivic” or the “Company”, NASDAQ: TIVC), a developer in the electromedical and electrotherapeutic device sector, has released its preliminary financial results for the full year ended December 31, 2025, and provided a significant business update that could have material impact on its future prospects and share price.
Key Financial Highlights for FY 2025
-
Net Loss from Continuing Operations: Tivic reported an expected net loss before discontinued operations in the range of \$7.9 million to \$8.1 million for 2025, compared to a net loss of \$4.5 million in 2024.
-
Net Loss Including Discontinued Operations: The total net loss, which includes discontinued operations, is anticipated to be between \$8.8 million and \$9.1 million, a notable increase from \$5.7 million in the prior year.
-
Discontinued Operations: Loss from discontinued operations decreased by \$300,000 to \$900,000 for 2025. This relates to all activities associated with the consumer product business, which the Company exited during the year.
-
Cash Position: As of December 31, 2025, Tivic’s cash and equivalents totaled \$12.6 million, a remarkable increase from \$2.0 million at the end of 2024. The Company reported a working capital of \$12.4 million at year-end 2025.
Significant Corporate Developments
-
Exit from Consumer Product Business: In 2025, Tivic fully exited its consumer product business. All operations related to this segment are now classified as discontinued operations. The exit is expected to allow Tivic to focus on its core medical device and bioworks strategies.
-
Major Debt Financing and Asset Acquisition: On December 10, 2025, Tivic entered into a \$16.3 million Senior Secured Convertible Note Payable. All proceeds from this debt offering were utilized to acquire assets now used by the Company’s new Velocity Bioworks division. Tivic is in the process of finalizing certain accounting matters related to this substantial transaction.
Potentially Price-Sensitive Information
-
Strategic Shift and New Business Focus: The discontinuation of the consumer product segment marks a major strategic shift. Investors should note that Tivic is now positioning itself around the newly acquired assets and the development of Velocity Bioworks. The outcome of this transition, and the Company’s ability to realize benefits from its new focus, could materially affect its future performance and share value.
-
Increased Losses but Stronger Liquidity: While net losses have widened compared to the prior year—partly due to the strategic transition and acquisition-related costs—the significant increase in cash and working capital provides Tivic with a stronger liquidity position to pursue new opportunities.
-
Pending 10-K Filing: The Company reminded investors that its Form 10-K for FY2025 will be filed on or before March 31, 2026. Investors should monitor this filing for important final audited figures and further disclosures that could impact the Company’s outlook and share price.
Conference Call and Webcast Details
Tivic will host a conference call to discuss its 2025 results:
Forward-Looking Statements
This release contains forward-looking statements, including those regarding the Company’s strategic direction, the anticipated benefits from the Velocity Bioworks asset acquisition, ongoing regulatory interactions, and future financial performance. These statements involve substantial risks and uncertainties, including but not limited to those related to regulatory processes, market conditions, the successful execution of strategic shifts, and the Company’s ability to maintain its Nasdaq listing. Actual results may differ materially from those expressed or implied.
Contact
- Investor Contact: Hanover International, Inc. ([email protected])
- Media Contact: DJ Freyman
Disclaimer: The above article is based on preliminary unaudited financial results and management disclosures. Actual results may vary following the completion of the annual audit process and the filing of the Form 10-K. Forward-looking statements are subject to change and investors are urged to review the Company’s SEC filings and consult with their financial advisors before making investment decisions. This article does not constitute investment advice.
View Tivic Health Systems, Inc. Historical chart here
